A patient messages you with a monthly headache diary showing frequent moderate-to-severe migraine days, incomplete relief and nausea with an oral triptan, and no red-flag symptoms, asking whether to change acute treatment and start a preventive. Reviewing that structured headache history and attack log, you choose a non-oral triptan or a gepant for acute attacks, start an 8-to-12-week preventive trial at a target dose, and follow that same patient in one continuous thread over the months ahead. That outpatient work addresses a wide gap in access: in 2018 US government health surveys, age-adjusted migraine or severe headache prevalence was 15.9% of adults (Burch et al., Headache, January 2021), while nationwide there were 692 UCNS-certified headache subspecialists in 2021 (Kanegi and Rosen, Headache, November 2022). The American Headache Society's (AHS) March 2026 position statement (Headache) noted that access to specialized headache care is "severely limited" by the "paucity of clinicians with specialized training and experience in headache medicine," with "few if any" specialists in some states, and among 163,313 Medicare beneficiaries in 2018 to 2019, the median referral wait for a first neurologist visit was 34 days (Lin et al., Neurology, February 2025).

One patient's year in an outpatient headache clinic

1. The history and the headache diary

Most outpatient migraine decisions rely on history and attack logs. Per the National Institute of Neurological Disorders and Stroke (August 10, 2026), doctors diagnose migraine from the health history and physical and neurological exams, while MRI or CT scans "aren't usually used to diagnose migraine." AHS Choosing Wisely (American Family Physician, April 2020) advises against imaging stable headaches meeting migraine criteria, and the AHS March 2026 statement notes that the overwhelming majority of headache patients have a normal neurological exam and secondary causes are commonly identified from the history. Across the year, the patient's headache diary tracks monthly migraine days, moderate-to-severe headache days, attack severity, disability, and days of acute medication use.

2. Choosing and adjusting acute treatment

Per the AHS 2021 consensus (Ailani et al., Headache, July 2021; MDedge, July 2021), mild to moderate attacks use NSAIDs, acetaminophen, or caffeine combinations; moderate to severe attacks use triptans, gepants, or ditans at pain onset. About 30% on triptans respond insufficiently and may try a second triptan, gepant, ditan, or device; severe nausea or vomiting calls for non-oral forms. Frequent rimegepant or ubrogepant does not appear to cause medication-overuse headache, and gepants and ditans appeared safe with stable cardiovascular disease. FutureClinic doctors do not prescribe controlled substances, matching AHS Choosing Wisely against first-line opioids or butalbital for recurrent headache and excluding Schedule V lasmiditan (21 CFR 1308.15, October 22, 2026), while keeping triptans, gepants, self-injected CGRP antibodies, beta-blockers, and antiepileptics in scope.

3. Running an 8-to-12-week preventive trial

When the diary shows frequent attacks, the next step in the patient's year is a preventive trial. The August 2026 American Academy of Neurology (AAN) and AHS guideline offers prevention at 4 or more monthly migraine or moderate-to-severe headache days, or substantial disability (Level B), listing atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, propranolol, topiramate, and valproate for episodic migraine efficacy. The AHS April 2024 statement (Charles et al., Headache) makes CGRP therapies (erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant) first-line without prior failures. Insurers still often require prior authorization for CGRP step therapy, which was required by 96% of policies across 47 managed-care organizations (Musial and Kheloussi, American Journal of Managed Care, April 2023) and remained common 10 months after the AHS 2024 update (Moskatel and Slusky, Headache, April 2026). Most preventives require 8 to 12 weeks at a tolerated target dose (raising weak 8-week responses to maximum tolerated) while tracking medication overuse (over 9 prescription or 14 nonspecific analgesic days monthly).

4. Red flags and procedures that require an exam or emergency care

In-person or emergency care is needed for SNNOOP10 red flags (Do et al., Neurology, January 2019; "A minority of headache patients have a secondary headache disorder"): fever or systemic symptoms, neoplasm, neurologic deficit or decreased consciousness, sudden onset, onset after 65, pattern change or new headache, positional headache, sneeze, cough, or exercise triggers, papilledema, progressive or atypical course, pregnancy or puerperium, painful autonomic eye, posttraumatic onset, immune compromise such as HIV, and painkiller overuse or new drug at onset. The AHS March 2026 statement notes a local eye professional can do fundoscopy, advises "mechanisms for urgent or semiurgent referrals for in‐person visits" for suspected secondary headache or parenteral therapy, and says in-person care "may be more appropriate" for acute headache. Clinic visits are also needed for onabotulinumtoxinA (31 injections across 7 head and neck sites every 12 weeks, judged at 24 weeks; label November 2023), eptinezumab (quarterly IV; label June 2026), and cardiac evaluation (plus considering a supervised first dose and ECG) before triptans in triptan-naive patients with multiple cardiovascular risk factors (sumatriptan label December 2025; rizatriptan label June 2021).

What randomized telemedicine trials found in headache care

Randomized headache trials tested live video follow-up against office visits, while the AHS position statement also includes written electronic consultations under telemedicine; none of these trials tested direct patient-to-doctor messaging. At UT Southwestern, a one-year randomized trial of 45 patients with severe migraine disability (Friedman et al., Cephalalgia, October 2019) found no 12-month difference between video and office follow-up in MIDAS improvement, headache days, or severity, while video visits were shorter and more convenient. In Norway, a randomized noninferiority trial of 402 patients with nonacute headache (Müller et al., Neurology, July 2017) comparing one video (200) or office (202) visit found no difference in HIT-6 or pain scores at 3 or 12 months, with one secondary headache per group. The AHS March 2026 statement found telemedicine "consistently" noninferior on disability and satisfaction, endorsed it "when feasible and appropriate," and included "electronic consultations" that "involve written rather than spoken communication."

Shift-based teleneurology and scheduled outpatient roles

Hospital teleneurology centers on shifts. Access TeleCare (Doximity, August 3, 2026; site, October 21, 2026) hires for "virtual inpatient consults and telestroke care" in 8- and 12-hour shifts (8 am to 4 pm, 4 pm to midnight, midnight to 8 am Central; 11 monthly shifts part-time, 22 full-time). TeleSpecialists (careers page, read October 27, 2026) staffs TeleStroke ("industry leading three minutes response times"), TeleNeuroHospitalist rounding, TeleEEG, and outpatient care, stating "Off means off. No last-minute call-ins." NuView Telehealth (Paylocity, October 27, 2026) and a September 15, 2026 DocCafe recruiter post require "a minimum of 7 shifts per month" on hospital carts, and a Salem, Oregon Providence summary (SalaryDr, September 2026) lists "14 shifts/month of 12-hour shifts." These suit doctors wanting scheduled hospital shifts.

In outpatient care, Neura Health (Greenhouse, February 27, March 20, September 22, 2026) requires "at least 8 hours of patient-facing availability per week" at "$160 per hour paid by appointment" (full-time: "40+ hours of patient-facing availability + 10 hours of administrative time"), pairing video visits with chat. Cove (October 25, 2026) offers message consults with "2 short diagnostic videos" reviewed within 48 hours under Cove's brand, naming no specialty. Neura suits doctors wanting set weekly video blocks.

How does your own headache clinic work on FutureClinic?

On FutureClinic, you open an outpatient clinic under your own name and treat patients by message on your own schedule, with no video queue and no shifts. Rather than logging into a fixed video queue or covering 8- or 12-hour hospital blocks on someone else's schedule, you set your weekly availability hours in your time zone, choose your patient volume and conditions, and answer patients on your own time from your phone or computer when you choose, going private any time. You get a personal clinic page and link to bring your own patients, or you can pick up cases from an available pool of patients who came to FutureClinic. Patients stay with you in one chat for 8-to-12-week preventive checks and refills, or join a cancel-anytime monthly membership for ongoing care. You can also send an optional short video or voice note, the Human Signature, and patients can send videos too.

Before you open a case, FutureClinic's AI works like a chief resident: it takes the history, asks follow-ups you trained it on, and drafts a reply in your style to edit and sign, while screening out controlled substances and flagging possible emergencies. You read each case and make every medical decision yourself, practicing the longitudinal specialty care you trained for rather than approving forms in bulk, and FutureClinic sells no medicines or products. Prescribing to the patient's chosen pharmacy, lab orders with returning results, and imaging orders are built in, along with prior authorization help when an insurer requires step-therapy documentation. Doctors share one record, with patient-consented access to wider records and Apple Health, Android's Health Connect, Oura, and Garmin wearables.

As an independent 1099 physician (MD, DO, or MBBS) alongside over 300 doctors across more than 60 specialties, you set your own visit and membership prices, change them any time, or treat for free, with no setup, monthly, or minimum fees. FutureClinic keeps 25% of what you charge (you keep 75%), covering billing, refunds, 1099s, and malpractice from case one under the FutureClinic Medical Group's $5 million group policy with a $5 million excess layered on top and paid tail coverage if that policy ends. Payouts arrive at the start of every month, and you treat patients in your licensed states, with licensing partners to add states. FutureClinic believes this personal connection between patient and doctor is the future of healthcare for decades to come. Confirm your NPI in minutes by downloading the FutureClinic Doctors app, or start at https://futureclinic.com/doctors.